This paper reports the findings of a survey conducted with key stakeholders from pharmaceutical and diagnostic companies, as well as donor and research organizations, to (i) discern the main factors impeding private sector investment in tools to combat TB and (ii) garner proposed mechanisms to incentivize greater engagement.
PDF attached.
Nature Biotech 2019.pdf (793.9 KB)